Andelyn Biosciences, a US-based cell and gene therapy Contract Development and Manufacturing Organization (CDMO), and ENCell Co., a Korea-based advanced biopharmaceutical CDMO, have announced the signing of a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to accelerate the global delivery of life-changing gene therapies.
The partnership leverages both companies’ industry-leading GMP manufacturing facilities, technical expertise, and extensive regional networks to fast-track the development, manufacturing, and global expansion of client programs that deliver next-generation gene therapies to patients worldwide.
This partnership enables a streamlined 'dual hemisphere' workflow. By providing a direct route between US and APAC manufacturing hubs, the collaboration offers a simplified and cost-effective platform that removes the regulatory and logistical complexities of international expansion.
Most importantly, facilitating in-country manufacturing for in-country clinical trials ensures regional supply chains can meet the specific needs of local patient populations, greatly reducing lead times and accelerating the path to commercialisation.
